US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Director Dealing

16 February 2026 4basebio PLC ("4basebio" or the "Company") Director Dealing Cambridge, UK, 16 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 13 February 2026 it was informed that Dr. Amy Walker, Chief Executive Officer of the Company made the following purchase in ordinary shares in the capital of the Company through the market. Further details are set out in the Notification

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Wilhelm K. T. Zours City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name DELPHI Unternehmensberatung Aktiengesellschaft City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the

Result of AGM

27 June 2025 4basebio PLC ("4basebio" or the "Company") Result of AGM Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces the result of its Annual General Meeting held earlier today. The Company decided at the meeting to make certain amendments to Resolutions 14 to 16 which were therefore withdrawn and replacement resolutions will be put forward in due course.  All other resolutions were duly passed. For further enquiries, please contact:

Exercise of Options

25 June 2025 4basebio PLC ("4basebio" or the "Company") Exercise of Options Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that, on 19 June 2025, it received notification from two employees of the Company to exercise EMI options over 13,000 ordinary shares (“New Ordinary Shares”) in the Company at an exercise price of £1.18 per share, raising total proceeds of £15,340. Admission to AIM Application will be made for the New Ordinary

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Wilhelm K. T. Zours City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name DELPHI Unternehmensberatung Aktiengesellschaft City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Latonba AG City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above City of

Director's Dealing

29 November 2024 4basebio plc (“4basebio” or the "Company")  Director’s Dealing 29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that he acquired ordinary shares in the Company through the market as follows:  Name Number of Price per Shareholding Shareholding as a Shares Share (p) Following Percentage of Issued

Holding(s) in Company

TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible) [i] 1a. Identity of 4basebio PLCthe issuer or theunderlying issuerof existingsharesto which votingrights areattached[ii]:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer2. Reason for thenotification(please mark theappropriate boxorboxes with an“X”)An acquisition

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification Other Comments Off-market transfer of Shares of the Issuer 3. Details of person subject to the notification obligation Name Sparta AG City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation,

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification Other Comments Off-market transfer of Shares of the Issuer 3. Details of person subject to the notification obligation Name SPARTA Invest AG City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Employee Long Term Incentive Plan and Issue of Equity

18 July 2024   [A close-up of a logo Description automatically generated]          4basebio PLC ("4basebio" or the "Company")   Employee Long Term Incentive Plan and Issue of Equity   Cambridge, UK, 18 July 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that it has awarded 5,520 ordinary shares of EUR€1.00 each in the Company (“EBT Shares”) to the Employees Benefit Trust (“EBT”), operated by Fiduchi Trustees (UK) Limited at £15.60 per

Half-year Report

4basebio PLC("4basebio", the "Company" or the “Group”) Half-year Reportfor the six months ended 30 June 2023 4basebio PLC (AIM: 4BB), Cambridge, UK, 21 September 2023 – 4basebio PLC, an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces its unaudited half-year results for the six months ended 30 June 2023. Operational Highlights (including post period end) · DNA and Hermes™

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media